<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="pntd.0007860.t001" orientation="portrait" position="float">
 <object-id pub-id-type="doi">10.1371/journal.pntd.0007860.t001</object-id>
 <label>Table 1</label>
 <caption>
  <title>Summary of vaccine and/or passive immunization status for the neglected infectious diseases discussed in this Review.</title>
 </caption>
 <alternatives>
  <graphic id="pntd.0007860.t001g" xlink:href="pntd.0007860.t001" xmlns:xlink="http://www.w3.org/1999/xlink"/>
  <table frame="hsides" rules="groups">
   <colgroup span="1">
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
    <col align="left" valign="middle" span="1"/>
   </colgroup>
   <thead>
    <tr>
     <th align="justify" rowspan="1" colspan="1">Disease</th>
     <th align="justify" rowspan="1" colspan="1">Vaccine</th>
     <th align="justify" rowspan="1" colspan="1">Highest discovery status</th>
    </tr>
   </thead>
   <tbody>
    <tr>
     <td align="justify" rowspan="1" colspan="1">Dengue</td>
     <td align="justify" rowspan="1" colspan="1">CYD-TDV/Dengvaxia: Efficacy 60%–70%, but only given to persons with confirmed prior infection due to safety issues [
      <xref rid="pntd.0007860.ref042" ref-type="bibr">42</xref>].
     </td>
     <td align="justify" rowspan="1" colspan="1">Several mAbs, also with in vivo activity: SIgN-3C [
      <xref rid="pntd.0007860.ref043" ref-type="bibr">43</xref>], VIS513 [
      <xref rid="pntd.0007860.ref044" ref-type="bibr">44</xref>, 
      <xref rid="pntd.0007860.ref045" ref-type="bibr">45</xref>], D23-1B3B9 [
      <xref rid="pntd.0007860.ref046" ref-type="bibr">46</xref>–
      <xref rid="pntd.0007860.ref048" ref-type="bibr">48</xref>], and Mab11/mutFc [
      <xref rid="pntd.0007860.ref049" ref-type="bibr">49</xref>].
     </td>
    </tr>
    <tr>
     <td align="justify" rowspan="1" colspan="1">Fungal infections</td>
     <td align="justify" rowspan="1" colspan="1">No</td>
     <td align="justify" rowspan="1" colspan="1">Two mAbs in past human trials: 18B7 [
      <xref rid="pntd.0007860.ref050" ref-type="bibr">50</xref>] and Mycograb [
      <xref rid="pntd.0007860.ref051" ref-type="bibr">51</xref>]; many preclinical candidates.
     </td>
    </tr>
    <tr>
     <td align="justify" rowspan="1" colspan="1">HBV</td>
     <td align="justify" rowspan="1" colspan="1">Yes: Energix B and Recombivax HB; 80%–100% efficacy.</td>
     <td align="justify" rowspan="1" colspan="1">E6F6 is in clinical trials [
      <xref rid="pntd.0007860.ref052" ref-type="bibr">52</xref>].
     </td>
    </tr>
    <tr>
     <td align="justify" rowspan="1" colspan="1">HIV</td>
     <td align="justify" rowspan="1" colspan="1">No</td>
     <td align="justify" rowspan="1" colspan="1">One mAb (ibalizumab [
      <xref rid="pntd.0007860.ref013" ref-type="bibr">13</xref>]) has been approved. Eight mAb checkpoint inhibitors are in human trials, with PRO 140 and Cenicriviroc in Phase III.
     </td>
    </tr>
    <tr>
     <td align="justify" rowspan="1" colspan="1">Malaria</td>
     <td align="justify" rowspan="1" colspan="1">RTS,S is partially active 30%–50% [
      <xref rid="pntd.0007860.ref053" ref-type="bibr">53</xref>] and in confirmatory trials [
      <xref rid="pntd.0007860.ref054" ref-type="bibr">54</xref>].
     </td>
     <td align="justify" rowspan="1" colspan="1">mAbs with (prophylactic) in vivo activity, including CIS43 [
      <xref rid="pntd.0007860.ref055" ref-type="bibr">55</xref>, 
      <xref rid="pntd.0007860.ref056" ref-type="bibr">56</xref>] and checkpoint inhibitors.
     </td>
    </tr>
    <tr>
     <td align="justify" rowspan="1" colspan="1">Schistosomiasis</td>
     <td align="justify" rowspan="1" colspan="1">No</td>
     <td align="justify" rowspan="1" colspan="1">mAbs with in vivo activity: SJ18ε.1 [
      <xref rid="pntd.0007860.ref057" ref-type="bibr">57</xref>–
      <xref rid="pntd.0007860.ref059" ref-type="bibr">59</xref>].
     </td>
    </tr>
    <tr>
     <td align="justify" rowspan="1" colspan="1">Trypanosomiasis</td>
     <td align="justify" rowspan="1" colspan="1">No</td>
     <td align="justify" rowspan="1" colspan="1">An antibody–drug conjugate was active in vivo [
      <xref rid="pntd.0007860.ref060" ref-type="bibr">60</xref>].
     </td>
    </tr>
    <tr>
     <td align="justify" rowspan="1" colspan="1">TB</td>
     <td align="left" rowspan="1" colspan="1">The BCG vaccine (partially active).</td>
     <td align="justify" rowspan="1" colspan="1">Etanercept was trialed (reviewed in [
      <xref rid="pntd.0007860.ref061" ref-type="bibr">61</xref>]); mAbs with in vivo activity: 2E9IgA1 [
      <xref rid="pntd.0007860.ref062" ref-type="bibr">62</xref>], reviewed in [
      <xref rid="pntd.0007860.ref034" ref-type="bibr">34</xref>].
     </td>
    </tr>
    <tr>
     <td align="justify" rowspan="1" colspan="1">VL</td>
     <td align="justify" rowspan="1" colspan="1">No</td>
     <td align="justify" rowspan="1" colspan="1">Diagnostic antibodies only [
      <xref rid="pntd.0007860.ref063" ref-type="bibr">63</xref>].
     </td>
    </tr>
   </tbody>
  </table>
 </alternatives>
 <table-wrap-foot>
  <fn id="t001fn001">
   <p>Abbreviations: BCG, Bacillus Calmette–Guérin; CIS43, circumsporozoite protein 43; HBV, hepatitis B virus; mAb, monoclonal antibody; mutFc, mutated Fragment crystallizable region; TB, tuberculosis; VL, visceral leishmaniasis</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
